Enjoy complimentary customisation on priority with our Enterprise License!
The inflammatory bowel disease market size is forecast to increase by USD 7.62 billion at a CAGR of 5.48% between 2023 and 2028. The market is experiencing significant growth due to the increasing incidence of IBD worldwide and the subsequent demand for effective therapeutics. Notable new launches, such as Lilly's Mirikizumab, an oral JAK inhibitor, are revolutionizing the treatment landscape. However, the high cost of IBD therapeutics remains a major challenge, with patients and physicians seeking more affordable options. Reimbursement regulations also play a crucial role in market dynamics, with online pharmacies emerging as a potential solution for patients seeking cost savings. Despite these challenges, the market is expected to continue growing, driven by the unmet medical needs of IBD patients and the ongoing research and development of innovative therapeutic solutions.
Inflammatory Bowel Disease (IBD), primarily consisting of Crohn's disease and ulcerative colitis, is a chronic condition characterized by inflammation in the gastrointestinal tract. The disease is prevalent in industrialized countries, with environmental triggers and genetic predisposition being the key factors contributing to its development. The IBD market is witnessing significant growth due to the increasing number of clinical trials for new therapies. Biological drugs, such as Cimzia from UCB and Entyvio from Takeda, are leading the market, with injectable Janus kinase inhibitors like Jyseleca from Lilly and Jak inhibitors from Ferring Pharmaceuticals also gaining popularity. Allergan and Cytoreason are among the companies investing in research and development for novel IBD treatments.
Healthcare institutes, healthcare professionals, and healthcare systems are the major consumers of these therapies, as they cater to the growing demand for effective IBD treatments. Infections are a significant challenge in the management of IBD, necessitating continuous innovation in the field.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.
The offline segment is estimated to witness significant growth during the forecast period. The offline distribution channel plays a pivotal role in the market. This segment encompasses the sale and distribution of IBD therapeutics through conventional pharmacies and drugstores. Despite the increasing popularity of online distribution channels, the offline segment maintains its significance in the market. Consumers frequently prefer purchasing medications from physical stores due to the guarantee of instant availability and the opportunity for direct communication with pharmacists. This preference benefits the offline channel, enabling both established and emerging pharmaceutical companies to expand their consumer reach. CytoReason, a leading diagnostic solutions provider, plays a crucial role in the IBD market by offering advanced diagnostic techniques for disease detection.
Understanding the disease pathophysiology is essential for effective treatment, and CytoReason's technologies contribute significantly to this process. In the IBD market, drug classes such as biologics, including Entyvio from Ferring Pharmaceuticals, are increasingly being used for disease management. Environmental triggers, such as diet and stress, can exacerbate IBD symptoms, making early and accurate diagnosis vital. The offline channel's accessibility and convenience make it an essential partner in ensuring patients receive timely and appropriate treatment.
Get a glance at the market share of various segments Request Free Sample
The offline segment was valued at USD 17.34 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 37% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The market in North America is experiencing significant growth due to the rising incidence and prevalence of chronic gastrointestinal conditions, such as ulcerative colitis and Crohn's disease. According to the Centers for Disease Control and Prevention (CDC), over 2.6 million cases of IBD were diagnosed in the US in 2022. This increasing disease burden, coupled with growing healthcare expenditure, is driving market growth. Pharmaceutical and biotechnology companies are focusing on research and development (R&D) to introduce novel drugs for IBD treatment. CytoReason, Ferring Pharmaceuticals, and Entyvio are some of the notable players in the market. Diagnostic techniques play a crucial role in disease detection rates, and environmental triggers continue to be a significant factor in disease pathophysiology.
The presence of global and regional companies further fuels market expansion during the forecast period.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing incidence of IBD worldwide is the key driver of the market. The prevalence of inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, has witnessed a notable rise worldwide. Factors such as incorrect diets, sedentary lifestyles, stress, food sensitivities, and bacterial or viral infections are contributing to the increasing incidence of chronic gastrointestinal conditions. IBD, which causes inflammation of the gastrointestinal tract, affects an estimated 320,000 people in Canada in 2023, and this number is projected to reach 470,000 by 2035. Two of the most common forms of IBD are Crohn's disease and ulcerative colitis. Major pharmaceutical companies, such as AbbVie and Allergan, are actively involved in the development of biological drugs for the treatment of IBD.
For instance, AbbVie's Cimzia is a monoclonal antibody used for the treatment of Crohn's disease and other inflammatory conditions. Clinical trials are ongoing to evaluate the efficacy and safety of new treatments and therapies for IBD.
New launches of IBD therapeutics are the upcoming trend in the market. The market is experiencing significant growth due to the increasing focus of companies on the development of innovative therapeutics for various IBDs, including Crohn's disease and ulcerative colitis. Pharmaceutical and biopharmaceutical companies are investing heavily in research and development (R&D) to bring new treatments to market. Notable product launches include AbbVie's Cimzia (Certolizumab pegol), a PEGylated anti-TNF-? monoclonal antibody, which was approved by the US Food and Drug Administration (FDA) in 2014 for the treatment of Crohn's disease. More recently, in February 2021, Allergan's biologic drug, Humira (Adalimumab), a TNF blocker, received FDA approval for the treatment of Crohn's disease.
These advancements in therapeutics are transforming the IBD treatment landscape and providing new hope for patients.
The high cost of IBD therapeutics is a key challenge affecting the market growth. Inflammatory Bowel Diseases (IBDs), including Crohn's disease and ulcerative colitis, are chronic conditions that necessitate prolonged treatment to prevent recurrence and potential cancer development. The primary treatment modalities for IBDs involve the use of biologic drugs and small molecules. Companies such as AbbVie, with their Cimzia brand, and Allergan contribute significantly to the IBD market with their biologic offerings. Clinical trials are ongoing to explore the efficacy of these therapies. The cost structure for IBD treatments comprises the expense of medications, doctor consultations, and hospital visits or stays. For instance, the cost of treating ulcerative colitis averages between USD 6,000 and USD 12,000, while Crohn's disease treatment costs approximately USD 30,000 to USD 32,000.
Pfizer's Xeljanz oral tablets, used for ulcerative colitis treatment, typically cost around USD 4,900 to USD 5,000 for a supply of 60 tablets.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AstraZeneca Plc - The company offers inflammatory bowel disease solutions such as CAR-T therapy.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Inflammatory Bowel Disease (IBD), which includes Crohn's disease and ulcerative colitis, is a chronic gastrointestinal condition characterized by immune system disruption and inflammation. The disease burden is high in industrialized countries, with genetic predisposition and environmental triggers contributing to its development. Diagnostic techniques have improved, leading to higher disease detection rates, but the disease pathophysiology remains complex. Biological drugs, such as TNF inhibitors (Remicade, Humira, Simponi, and Cimzia), IL inhibitors (Entyvio), and JAK inhibitors (Rinvoq, Olumiant, and Jyseleca), are commonly used to manage IBD. The market for these drugs is growing due to the increasing number of patients and the development of new treatments.
Further, the market is segmented into TNF inhibitors and IL inhibitors. TNF inhibitors dominate the market due to their established safety and efficacy profile. However, the emergence of new classes of drugs, such as JAK inhibitors and toll-like receptor agonists, is expected to challenge the dominance of TNF inhibitors. The route of administration for IBD drugs includes injectable and oral forms. The availability of biosimilars and the trend towards patient-centric care, such as telemedicine and online pharmacies, are also impacting the market dynamics. Reimbursement regulations and healthcare systems' policies are key factors influencing the market growth.
Healthcare professionals, hospitals, healthcare institutes, retail pharmacies, and hospital pharmacies are the major end-users of IBD drugs.
Market Scope |
|
Report Coverage |
Details |
Page number |
170 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.48% |
Market Growth 2024-2028 |
USD 7.62 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
5.09 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 37% |
Key countries |
US, China, UK, India, and Canada |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Aurobindo Pharma Ltd., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Biocon Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.